• Mashup Score: 0
    Managing BTKis for Coverage - 1 year(s) ago

    Roy Beveridge, MD, discusses how payers and health systems are managing Bruton tyrosine kinase inhibitors and how they are chosen for formulary and pathway coverage.

    Source: AJMC
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AJMC_Journal
      AJMC_Journal

      In the eighth episode from our #PeerExchange series, "Bruton Tyrosine Kinase Inhibitors in Leukemia and Lymphoma," Dr Roy Beveridge discusses how payers and health systems are managing #BrutonTyrosineKinaseinhibitors. Watch now! https://t.co/Kj9KRGn0Gb https://t.co/bTdM2NNTbE

  • Mashup Score: 0
    Venetoclax in Previously Treated Waldenström Macroglobulinemia - PubMed - 2 year(s) ago

    Venetoclax is safe and highly active in patients with previously treated WM, including those who previously received BTKis. CXCR4 mutation status did not affect treatment response.

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SCIDirector
      SCIDirector

      SCI member Ranjana Advani and colleagues found venetoclax is safe and highly active in patients with previously treated #WaldenströmMacroglobulinemia, including those who previously received #BrutonTyrosineKinaseinhibitors. https://t.co/bx1Uxzrpnd